Five-Year Allograft Survival for Recipients of Kidney Transplants From Hepatitis C Virus Infected vs Uninfected Deceased Donors in the Direct-Acting Antiviral Therapy Era
Douglas E. Schaubel, Amelia H. Tran, Peter L. Abt, Vishnu S. Potluri, David S. Goldberg, Peter P. Reese
Abstract
This cohort study examines the validity of the Kidney Donor Profile Index’s hepatitis C virus (HCV) penalty during the direct-acting antiviral era by comparing 5-year allograft survival between recipients of kidneys from HCV-RNA–positive donors vs HCV-RNA–negative donors.
Topics & Concepts
MedicineHepatitis C virusAntiviral therapyCohortKidney transplantationKidneyVirologyHepatitis CInternal medicineVirusKidney transplantImmunologyChronic hepatitisHepatitis C virus researchRenal Transplantation Outcomes and TreatmentsLiver Disease and Transplantation